Abstract：
UNASSIGNED: Despite the fact incidence and mortality vary widely among regions, sepsis remains a major cause of morbidity and cost worldwide. The importance of the endothelial barrier in sepsis and infectious diseases is increasingly recognized; however, the underlying pathophysiology of the endothelial barrier in sepsis remains poorly understood.
UNASSIGNED: Here we review the advances in basic and clinical research for relevant papers in PubMed database. We attempt to provide an updated overview of immunological alterations in endothelial dysfunction, discussing the central role of endothelial barrier involved in sepsis to provide new predictive and therapeutic paradigm for sepsis.
UNASSIGNED: Given its physiological and immunological functions in infectious diseases, the endothelial barrier has been dramatically altered in sepsis, suggesting that endothelial dysfunction may play a critical role in the pathogenesis of sepsis. Although many reliable biomarkers have been investigated to monitor endothelial activation and injury in an attempt to find diagnostic and therapeutic tools, there are no specific therapies to treat sepsis due to its complex pathophysiology. Since sepsis is initiated by both hyperinflammation and immunoparalysis occurring simultaneously, a \'one-treatment-fits-all\' strategy for sepsis-induced immune injury and immunoparalysis is bound to fail, and an individualized \'precision medicine\' approach is required.
UNASSIGNED: Here we review the advances in basic and clinical research for relevant papers in PubMed database. We attempt to provide an updated overview of immunological alterations in endothelial dysfunction, discussing the central role of endothelial barrier involved in sepsis to provide new predictive and therapeutic paradigm for sepsis.
UNASSIGNED: Given its physiological and immunological functions in infectious diseases, the endothelial barrier has been dramatically altered in sepsis, suggesting that endothelial dysfunction may play a critical role in the pathogenesis of sepsis. Although many reliable biomarkers have been investigated to monitor endothelial activation and injury in an attempt to find diagnostic and therapeutic tools, there are no specific therapies to treat sepsis due to its complex pathophysiology. Since sepsis is initiated by both hyperinflammation and immunoparalysis occurring simultaneously, a \'one-treatment-fits-all\' strategy for sepsis-induced immune injury and immunoparalysis is bound to fail, and an individualized \'precision medicine\' approach is required.
摘要：
■尽管各地区的发病率和死亡率差异很大，脓毒症仍然是全球发病率和费用的主要原因。内皮屏障在脓毒症和感染性疾病中的重要性日益得到认可;然而,对脓毒症内皮屏障的潜在病理生理学仍知之甚少.
■在这里，我们回顾了PubMed数据库中相关论文的基础和临床研究进展。我们试图提供内皮功能障碍的免疫学改变的最新概述，探讨内皮屏障在脓毒症中的重要作用，为脓毒症提供新的预测和治疗模式。
■鉴于其在传染病中的生理和免疫功能，在脓毒症中内皮屏障发生了显著的改变,提示内皮功能障碍可能在脓毒症的发病机制中起关键作用。尽管已经研究了许多可靠的生物标志物来监测内皮活化和损伤，试图找到诊断和治疗工具。由于其复杂的病理生理学,目前尚无治疗脓毒症的特异性疗法.由于败血症是由同时发生的过度炎症和免疫麻痹引起的，脓毒症诱导的免疫损伤和免疫麻痹的“一刀切”策略必然会失败，需要一种个性化的“精准医学”方法。
■在这里，我们回顾了PubMed数据库中相关论文的基础和临床研究进展。我们试图提供内皮功能障碍的免疫学改变的最新概述，探讨内皮屏障在脓毒症中的重要作用，为脓毒症提供新的预测和治疗模式。
■鉴于其在传染病中的生理和免疫功能，在脓毒症中内皮屏障发生了显著的改变,提示内皮功能障碍可能在脓毒症的发病机制中起关键作用。尽管已经研究了许多可靠的生物标志物来监测内皮活化和损伤，试图找到诊断和治疗工具。由于其复杂的病理生理学,目前尚无治疗脓毒症的特异性疗法.由于败血症是由同时发生的过度炎症和免疫麻痹引起的，脓毒症诱导的免疫损伤和免疫麻痹的“一刀切”策略必然会失败，需要一种个性化的“精准医学”方法。
